Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

110.12
-1.6700-1.49%
Post-market: 110.120.00000.00%19:30 EDT
Volume:1.05M
Turnover:118.01M
Market Cap:9.16B
PE:-34.28
High:116.20
Open:111.79
Low:109.41
Close:111.79
52wk High:130.05
52wk Low:54.09
Shares:83.15M
Float Shares:66.33M
Volume Ratio:1.41
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.07
PE(LYR):-29.84

Loading ...

Kymera Therapeutics Q2 EPS USD -0.62

THOMSON REUTERS
·
Aug 05

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

THOMSON REUTERS
·
Aug 05

Kymera Therapeutics (KYMR) Could Be 23% Undervalued On Its New CMO Appointment

Simply Wall St.
·
Aug 02

Kymera Therapeutics Inc : Deutsche Bank Initiates Coverage with Hold Rating; Target Price $120

THOMSON REUTERS
·
Jul 30

Kymera Therapeutics Schedules Quarterly Financial Results Webcast

Reuters
·
Jul 29

Kymera Therapeutics price target raised to $135 from $125 at Guggenheim

TIPRANKS
·
Jul 28

Kymera Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer Terence Rooney

Reuters
·
Jul 28

Kymera Therapeutics Appoints Terence Rooney, Md, as Chief Medical Officer

THOMSON REUTERS
·
Jul 28

Press Release: Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Dow Jones
·
Jul 28

Mizuho Raises Price Target on Kymera Therapeutics to $140 From $120, Keeps Outperform Rating

MT Newswires Live
·
Jul 16

Kymera Therapeutics Inc : Mizuho Raises Target Price to $140 from $120

THOMSON REUTERS
·
Jul 16

Kymera Therapeutics Shares Fall After RBC Downgrade

MT Newswires Live
·
Jul 14

Kymera Therapeutics Cut to Sector Perform from Outperform by RBC Capital

Dow Jones
·
Jul 13

U.S. Stocks on the Move-american Express, Deckers, Q32 Bio

Reuters
·
Jul 13

RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk

MT Newswires Live
·
Jul 13

Kymera Therapeutics Inc : RBC Cuts to Sector Perform from Outperform; Raises Target Price to $115 from $106

THOMSON REUTERS
·
Jul 13

Does Leadership Hire And Benchmark Additions Change The Bull Case For Kymera Therapeutics (KYMR)?

Simply Wall St.
·
Jul 11

Kymera CEO Nello Mainolfi Disposes of USD 5.95 Million in Common Shares

Reuters
·
Jul 08

Kymera Therapeutics Appoints Elizabeth Laws as SVP, Kt-621 Development Program Leader

Reuters
·
Jul 07

Kymera Therapeutics Appoints Elizabeth Laws, Ph.d., as Senior Vice President, Global Program Team Leader for Kt-621, First-in-class, Oral Stat6 Degrader

THOMSON REUTERS
·
Jul 07